Last reviewed · How we verify
carboplatin (Cb)
Carboplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Carboplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. Used for Ovarian cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | carboplatin (Cb) |
|---|---|
| Also known as | kabo |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This mechanism is achieved through the formation of platinum-DNA adducts, which cause DNA damage and trigger apoptosis in rapidly dividing cancer cells. The platinum atom in carboplatin binds to DNA, leading to the formation of cross-links and other DNA damage, which ultimately results in cell death.
Approved indications
- Ovarian cancer
- Non-small cell lung cancer
- Breast cancer
- Testicular cancer
- Urothelial cancer
Common side effects
- Myelosuppression
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anorexia
- Hair loss
- Neuropathy
Key clinical trials
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (PHASE2)
- Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (PHASE2)
- Aromatherapy in the Treatment of Early Breast Cancer (PHASE2)
- Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (PHASE3)
- Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |